Retatrutide
LY3437943
Retatrutide is a novel triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors for superior metabolic effects. This innovative approach produces enhanced appetite suppression, improved insulin sensitivity, and increased energy expenditure, potentially delivering 20-25% weight loss in clinical trials.
Complete Dosing Guide
Quick Reference
2.4-12
Typical Dose
Weekly
Frequency
5-7
Half-Life
SubQ
Route
Administration Method
Subcutaneous injection once weekly
Step-by-Step Dosing Protocol
Initial
2.4-12 mg weekly
Getting started
Follow gradual escalation approach
Maintenance
Optimized dose
Sustained benefits
Continue at effective dose
Cycling
Break period
Recovery
Take breaks to maintain effectiveness
Dosage Calculator
Dose Calculator
Peptide amount must be greater than 0
Medical Disclaimer
Retatrutide is currently in Phase 3 clinical trials and is not yet FDA approved. This information is for educational purposes only and should not replace medical advice. Consult with healthcare providers familiar with investigational therapies for personalized guidance. Side effects and contraindications are based on available clinical trial data.